Recombinant Human ARTN protein

ARTN (Artemin) is a secreted protein belonging to the glial cell line-derived neurotrophic factor (GDNF) family, which includes GDNF, neurturin, and persephin. It plays critical roles in nervous system development, maintenance, and repair by activating the RET tyrosine kinase receptor through a multi-component complex involving GDNF family receptor alpha-3 (GFRα3). ARTN is particularly associated with promoting neuronal survival, axon guidance, and nociceptive sensory neuron development. Its expression is observed in peripheral tissues and the central nervous system, with dysregulation linked to neuropathic pain, neurodegenerative disorders, and cancer progression.

Recombinant ARTN protein is typically produced using engineered expression systems (e.g., E. coli, mammalian cells) to ensure proper folding and bioactivity. The purified protein retains the ability to bind GFRα3 and activate downstream signaling pathways like MAPK/ERK and PI3K/AKT. Researchers utilize ARTN recombinant proteins to study neuroregeneration mechanisms, pain sensitivity pathways, and cancer biology, particularly in tumors with RET or GFRα3 overexpression, such as breast cancer and neuroblastoma. Recent studies also explore its therapeutic potential in nerve injury models and chemotherapy-induced neuropathy. Structural analyses often highlight conserved cysteine residues critical for its tertiary structure and receptor interaction. Commercial preparations usually undergo rigorous endotoxin testing and functional validation (e.g., neurite outgrowth assays) to ensure experimental reproducibility.